Rep. Thompson and Rep. Kelly Introduce Mental Health Research Accelerator Act to Speed Up Brain Disease Cures
The Mental Health Research Accelerator Act of 2025 is currently in the early stages of the legislative process. It was recently sent to the House Committee on Ways and Means for review. The bill is actively moving forward as it waits for the committee to consider it.
The bill has support from both parties and the sponsors sit on the committee that handles taxes. However, many tax bills struggle to pass unless they are part of a larger package.
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 5821 (118th), which died when its Congress ended.
H.R. 5821 (118th) →Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small biotech and pharmaceutical companies working on brain disease treatments could claim a 25% tax credit on their research expenses. This is a substantial incentive that could make it financially viable for smaller firms to take on the risky, expensive work of developing new neurological and psychiatric treatments. The credit is part of the general business credit, making it accessible to for-profit entities of all sizes.
“the translational research credit determined under this section for any taxable year shall be an amount equal to 25 percent of the amounts paid or incurred by the taxpayer during such taxable year”
Referred to the House Committee on Ways and Means.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Mental Health Research Accelerator Act of 2025
Analysis generated by AI. Always verify with official sources.